Cargando…

Extended therapy breaks from VEGFR TKI therapy in renal cell carcinoma: Sometimes less is more

Detalles Bibliográficos
Autores principales:	Zahoor, Haris, Rini, Brian I., Ornstein, Moshe C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865648/ https://www.ncbi.nlm.nih.gov/pubmed/29581822 http://dx.doi.org/10.18632/oncotarget.23005

Ejemplares similares

The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma
por: Barata, Pedro Coelho, et al.
Publicado: (2018)

Sometimes, less is just less…
por: Brotherton, B. Jason
Publicado: (2021)

Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma
por: Lai, Yongchang, et al.
Publicado: (2018)

Active repression by unliganded retinoid receptors in development: less is sometimes more
por: Weston, Andrea D., et al.
Publicado: (2003)

Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis
por: Bracarda, S, et al.
Publicado: (2012)

Chronic pain treatment in children and adolescents: less is good, more is sometimes better
por: Hechler, Tanja, et al.
Publicado: (2014)

When less is more: failure to adapt to local conditions sometimes boosts resilience
por: Haynes, Alison
Publicado: (2021)

Management of VEGFR-Targeted TKI for Thyroid Cancer
por: Enokida, Tomohiro, et al.
Publicado: (2021)

Study of Cathepsin B inhibition in VEGFR TKI treated human renal cell carcinoma xenografts
por: Chen, Chun-Hau, et al.
Publicado: (2019)

Beta-1-Adrenergic Receptor Antibodies in Acute Coronary Syndrome: Is Less Sometimes More?
por: Ernst, Diana, et al.
Publicado: (2018)

Radioiodine for thyroid cancer: sometimes, less is best
por: Padovani, Rosalia do Prado
Publicado: (2016)

Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab
por: Zahoor, Haris, et al.
Publicado: (2018)

Sometimes Less Is More: Perinatal Bacterial Exposure May Be More Important than Hepatitis for Liver Tumor Development
por: Taylor, David A.
Publicado: (2008)

Local anesthetic systemic toxicity following erector spinae plane block: sometimes less is more
por: Hamilton, Duncan Lee
Publicado: (2021)

Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma
por: Wang, Xiaoen, et al.
Publicado: (2016)

Addition of Salvage Immunotherapy to Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma
por: Dawsey, Scott J., et al.
Publicado: (2021)

PD-L1 Upregulation by the mTOR Pathway in VEGFR-TKI–Resistant Metastatic Clear Cell Renal Cell Carcinoma
por: Jeong, Se Un, et al.
Publicado: (2023)

Evaluation of T cell infiltration in matched biopsy and nephrectomy samples in renal cell carcinoma
por: Zahoor, Haris, et al.
Publicado: (2018)

Aneurysm and Artery Dissection After Oral VEGFR-TKI Use in Adults With Cancer
por: Kang, Soyoung, et al.
Publicado: (2023)

Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor
por: Ornstein, Moshe C., et al.
Publicado: (2023)

A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy
por: Ornstein, Moshe C., et al.
Publicado: (2019)

Sometimes Less Is Not Enough: A Commentary on Greiff et al. (2015)
por: Kretzschmar, André
Publicado: (2017)

Correction to: Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor
por: Ornstein, Moshe C., et al.
Publicado: (2023)

Ultrasound Molecular Imaging of Renal Cell Carcinoma: VEGFR targeted therapy monitored with VEGFR1 and FSHR targeted microbubbles
por: Ingels, Alexandre, et al.
Publicado: (2020)

An In Vitro Analysis of TKI-Based Sequence Therapy in Renal Cell Carcinoma Cell Lines
por: Zaccagnino, Angela, et al.
Publicado: (2023)

Sometimes
Publicado: (1867)

Sometime
Publicado: (1875)

Sometimes
Publicado: (1878)

Making sense of science: Sometimes plagiarized, sometimes not!
por: Nichani, Ashish Sham
Publicado: (2015)

The evolution of barriers to exploitation: Sometimes the Red Queen can take a break
por: Goodman, Jonathan R., et al.
Publicado: (2021)

Sometimes, More Is More: Antiseizure Medication polytherapy Is Associated With Decreased SUDEP Risk
por: Lee, Jong Woo
Publicado: (2021)

The Role of Targeted Therapy in Metastatic Renal Cell Carcinoma
por: Unnithan, Jaya, et al.
Publicado: (2007)

Dose-Dependent Beneficial Effect of Ketone Supplement-Evoked Ketosis on Anxiety Level in Female WAG/Rij Rats: Sometimes Less Is More
por: Rauch, Enikő, et al.
Publicado: (2023)

Clinical impact of early response to first‐line VEGFR‐TKI in patients with metastatic renal cell carcinoma on survival: A multi‐institutional retrospective study
por: Sobu, Ryuta, et al.
Publicado: (2022)

Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade
por: Ishibashi, Kei, et al.
Publicado: (2017)

Case Report: Gastrointestinal PEComa With TFE3 Rearrangement Treated With Anti-VEGFR TKI Apatinib
por: Xu, Jiaming, et al.
Publicado: (2020)

The Concept of Hormesis in Cancer Therapy – Is Less More?
por: Gaya, Andy, et al.
Publicado: (2015)

OPtimal Treatment by Invoking biologic clusters in renal cell carcinoma (OPTIC RCC)
por: Beckermann, Kathryn, et al.
Publicado: (2023)

Real-Life Effectivity of Dose Intensity Reduction of First-Line mFOLFIRI-Based Treatment of Metastatic Colorectal Cancers: Sometimes Less Is More
por: Pécsi, Balázs, et al.
Publicado: (2023)

Sometimes, often
por: Sandhu, Simran
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_veaq495ta91s3eafb74ghncf8m